oxalis deppei/fatigue

The link is saved to the clipboard

Choose sort type

12 results

Extended fatigue life of a catalyst free self-healing acrylic bone cement using microencapsulated 2-octyl cyanoacrylate.

Only registered users can translate articles

The tissue adhesive 2-octyl cyanoacrylate (OCA) was encapsulated in polyurethane microshells and incorporated into bone cement to form a catalyst free, self-healing bone cement comprised of all clinically approved components. The bending strength, modulus, and fatigue lifetime were investigated in

Clinical Review Report: Obeticholic Acid (Ocaliva): (Intercept Pharmaceuticals Canada, Inc.): Indication: For the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA

Only registered users can translate articles

Primary biliary cholangitis (PBC) occurs as a result of immune-mediated damage to bile ducts, with an associated inflammatory response leading to progressive fibrosis and loss of patency. This loss of patency leads, in turn, to hepatic accumulation of bile acids, resulting in liver damage with

Current and promising therapy for primary biliary cholangitis.

Only registered users can translate articles

Primary biliary cholangitis is a chronic, cholestatic liver disease that may progress to cirrhosis with complications of end-stage liver disease. Approved treatment options include ursodeoxycholic acid (UDCA) and obeticholic acid (OCA) but novel therapies are being

[Immune-mediated cholangiopathies : Diagnostic and therapeutic challenges].

Only registered users can translate articles

Immune-mediated cholangiopathies comprise primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC) and IgG4-associated cholangitis (IAC). A common feature is the progressive destruction of bile ducts leading to cholestasis with fibrosis and cirrhosis of the liver over

[Primary biliary cholangitis-established and novel therapies].

Only registered users can translate articles

Patients with primary biliary cholangitis (PBC, formerly primary biliary cirrhosis) and insufficient treatment response or risk factors exhibit a remarkably increased risk for disease progression and associated complications. Furthermore, extrahepatic manifestations may considerably reduce quality

What Comes after Ursodeoxycholic Acid in Primary Biliary Cholangitis?

Only registered users can translate articles

Primary biliary cholangitis (PBC) is a rare autoimmune liver disease characterized by chronic cholestasis. Treatment with the accepted primary therapy ursodeoxycholic acid (UDCA) has been shown to be associated with delayed disease progression probably through reduced impact of cholestatic injury on

Clinical Management of Primary Biliary Cholangitis-Strategies and Evolving Trends.

Only registered users can translate articles

PBC is a chronic progressive autoimmune disorder involving the destruction of intrahepatic small bile ducts, cholestasis, fibrosis, and ultimately cirrhosis if left untreated. It is largely driven by the autoimmune response, but bile acids and the intestinal microbiota are implicated in disease

Trial of Essiac to ascertain its effect in women with breast cancer (TEA-BC).

Only registered users can translate articles

BACKGROUND Breast cancer is a major cause of morbidity, mortality, and medical expenditures among women in Canada. Essiac (Resperin Canada Limited, Waterloo, Ontario, Canada), a blend of at least four herbs (burdock root [Arctium lappa], Indian rhubarb [Rheum palmatum], sheep sorrel [Rumex

Update on Emerging Treatment Options for Primary Biliary Cholangitis

Only registered users can translate articles

Primary biliary cholangitis (PBC) is a rare autoimmune cholestatic liver disease that may progress to fibrosis or cirrhosis. Treatment options are currently limited. Ursodeoxycholic acid (UDCA) remains first-line therapy and has been proven to normalize serum biochemistries, halt histologic disease

Nanohybrid and microfilled hybrid versus conventional hybrid composite restorations: 5-year clinical wear performance.

Only registered users can translate articles

The 5-year findings of a randomized clinical trial testing the null hypothesis that there are no differences between the clinical-wear performances of nano-, microfilled-, and conventional hybrids placed in class I and class II cavities are reported. Effects of subject-, operator-, and

Effects of cyclic loading on occlusal contact area wear of composite restoratives.

Only registered users can translate articles

OBJECTIVE To investigate the effects of cyclic loading on occlusal contact area (OCA) wear and the possible presence of fatigue wear mechanisms in four composite resins (Silux, Z100, Ariston and Surefil) using a reciprocal compression-sliding test apparatus. METHODS Six specimens were made for each

Three-year randomized clinical trial to evaluate the clinical performance and wear of a nanocomposite versus a hybrid composite.

Only registered users can translate articles

OBJECTIVE Compare the 3-year clinical performance (wear as an additional parameter) of a nanocomposite and a microhybrid composite, versus ADA guidelines (2001) using direct (clinical/USPHS) and indirect (quantitative/3D laser scan and qualitative/SEM) methods, in parallel. METHODS 18 Filtek Supreme

Join our facebook page

Herbal & Natural Medicine

The most complete medicinal herbs database backed by science

Works in 55 languages
Herbal cures backed by science
Herbs recognition by image
Interactive GPS map - tag herbs on location (coming soon)
Read scientific publications related to your search
Search medicinal herbs by their effects
Organize your interests and stay up do date with the news research, clinical trials and patents

Type a symptom or a disease and read about herbs that might help, type a herb and see diseases and symptoms it is used against.
*All information is based on published scientific research